Evidence

QuantHealth is trusted by the world's top biopharma to support their key clinical development decisions. With over 600 simulated trials, achieving up to 90% preditive accuracy, QuantHealth now has the industry's most advanced clinical trial simulation portfolio.

See How it Works

Broad Coverage Across all Therapeutic Areas,
Clinical Phases, and Treatment Modalities

Total
1738000512-evidence-graph-1
By Modality
1738000512-evidence-graph-2
By Phase
1738000512-evidence-graph-3
By Novelty
1738000512-evidence-graph-4

Prospectively Validated

Predicting trial results before readout, without sponsor data, with 85% accuracy on the primary endpoint

IMVOKE010:

Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (scchn)

  • Simulated Results 1738068291-imvoken010-simulated-results
  • Actual Results 1736961338-imvoke010-2
1

TROPION-Breast01:

A phase III open-label, randomized study of Dato-DXd versus investigator's choice of chemotherapy (ICC) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy

  • Simulated Results 1738068513-tropion-breast01
  • Actual Results 1736962602-tropion-breast01-2
2

ELOQUENT1

Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma

  • Simulated Results 1738068291-eloquent1
  • Actual Results 1736962717-elqquent1-2 (1)
3
For more Evidence

Case Studies

Explore the Power of Clinical Simulation

Book a Meeting